

### Syngene's Q4 FY2021 & Full Year FY2021 Results Conference Call

At 03:00 pm IST on 28<sup>th</sup> April 2021

The management team of Syngene International Limited ("Syngene") will organize a **conference call for Analysts and Investors on Wednesday, 28<sup>th</sup> April at 03.00 pm IST** following the announcement of financial results for the quarter and year ended March 31, 2021.

The call will be initiated with a brief management discussion on the Q4 FY2021 and full year FY2021 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene's Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

<b>Date:</b>	Wednesday, 28th April 2021
<b>Time:</b>	03:00 pm to 04:00 pm IST
<b>Dial-in Numbers*</b>	
Primary Number	+91 22 6280 1279 / +91 22 7115 8180
International Numbers	<ul style="list-style-type: none"> <li>USA – 18667462133 (Toll Free) /+13233868721 (Toll)</li> <li>UK – 08081011573 (Toll Free) /+442034785524 (Toll)</li> <li>Singapore – 8001012045 (Toll Free) /+6531575746 (Toll)</li> <li>Hong Kong – 800964448 (Toll Free) /+85230186877 (Toll)</li> <li>Australia – 1800053698 (Toll Free)</li> </ul>
Pre-registration Facility (DiamondPass™ link)	<p>Step 1: Pre-register <a href="#">here</a>. You will receive a passcode and a pin for the call on the registered email address.</p> <p>Step 2: Dial into the call on the Conference Call date, enter the passcode &amp; pin as prompted. You will be directly connected to the call</p>

\*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time

# Syngene

Putting Science to Work

Confidentiality

Quality

Innovation

Science

## INVESTOR CONFERENCE CALL INVITE

Q4 FY 2020-21

Replay Facility	Dial in numbers: +91 22 7194 5757 / +91 22 6663 5757 Playback ID: 60830 The replay facility will be available from 28 <sup>th</sup> April 2021 till 05 <sup>th</sup> May 2021
Conference Call Transcript	Will be available within 7 working days of the call on the corporate website: <a href="https://syngeneintl.com/">https://syngeneintl.com/</a>

### About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4000 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KGaA. For more details, visit <https://www.syngeneintl.com/>

### For further information, please contact:

Krishnan G

Syngene International

☎: +91 8068919807

✉: [Krishnan.G@syngeneintl.com](mailto:Krishnan.G@syngeneintl.com)

**Disclaimer:** Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.